Mesenchymal Stem Cell Therapy in Kidney Diseases: Potential and Challenges

Kidney disease (KD) is a life-threatening disease characterized by high morbidity and mortality in clinical settings, which can be caused by many reasons, and the incidence increases with age. However, supportive therapy and kidney transplantation still have limitations in alleviating KD progression...

Full description

Saved in:
Bibliographic Details
Published in:Cell Transplantation Vol. 32; p. 9636897231164251
Main Authors: Chen, Fukun, Chen, NaNa, Xia, Chunjuan, Wang, Hongyue, Shao, Lishi, Zhou, Chen, Wang, Jiaping
Format: Book Review Journal Article
Language:English
Published: Los Angeles, CA SAGE Publications 01-01-2023
Sage Publications Ltd
SAGE Publishing
Subjects:
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Kidney disease (KD) is a life-threatening disease characterized by high morbidity and mortality in clinical settings, which can be caused by many reasons, and the incidence increases with age. However, supportive therapy and kidney transplantation still have limitations in alleviating KD progression. Recently, mesenchymal stem cells (MSCs) have shown great potential in repairing injury through their multidirectional differentiation and self-renewal ability. Of note, MSCs serve as a safe and effective therapeutic strategy for treating KD in preclinical and clinical trials. Functionally, MSCs ameliorate KD progression by regulating the immune response, renal tubular cell apoptosis, tubular epithelial–mesenchymal transition, oxidative stress, angiogenesis, and so on. In addition, MSCs exhibit remarkable efficacy in both acute kidney injury (AKI) and chronic kidney disease (CKD) through paracrine mechanisms. In this review, we outline the biological characteristics of MSCs, discuss the efficacy and mechanisms of MSCs-based therapy for KD, summarize the completed and ongoing clinical trials, as well as analyze limitations and new strategies, aiming to provide new ideas and approaches for the preclinical experiments and clinical trials of MSCs transplantation for KD.
Bibliography:ObjectType-Article-2
SourceType-Scholarly Journals-1
ObjectType-Feature-3
content type line 23
ObjectType-Review-1
Fukun Chen and NaNa Chen are co-first authors and equally contributed to this work.
ISSN:0963-6897
1555-3892
DOI:10.1177/09636897231164251